Inovio Pharmaceuticals Inc. (INO) News

Inovio Pharmaceuticals Inc. (INO): $9.75

0.45 (-4.41%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add INO to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#241 of 362

in industry

Filter INO News Items

INO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest INO News From Around the Web

Below are the latest news stories about INOVIO PHARMACEUTICALS INC that investors may wish to consider to help them evaluate INO as an investment opportunity.

The 3 Most Undervalued Biotech Stocks to Buy: November 2023

Given the undervalued biotech industry, these three undervalued biotech stocks to buy are ripe purchase targets for high-potential profits.

Gabriel Osorio-Mazzilli on InvestorPlace | November 14, 2023

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2023 Earnings Call Transcript

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2023 Earnings Call Transcript November 9, 2023 Inovio Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.13 EPS, expectations were $-0.13. Operator: Good afternoon, ladies and gentlemen and welcome to the Inovio Third Quarter 2023 Financial Results Conference Call. At this time all lines are in a listen-only […]

Yahoo | November 10, 2023

Inovio Pharmaceuticals (INO) Q3 2023 Earnings Call Transcript

Good afternoon, and thank you for joining the Inovio 2023 third quarter conference call. Joining me on today's call are Dr. Jackie Shea, president and CEO; Dr. Michael Sumner, chief medical officer; Mr.

Yahoo | November 10, 2023

INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2023.

Yahoo | November 9, 2023

INOVIO Reports Inducement Grants Under Inducement Plan

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").

Yahoo | November 1, 2023

INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that third quarter 2023 financial results will be released after the market close on November 9, 2023. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.

Yahoo | October 26, 2023

Inovio Pharma (INO) Stock Surges 19% This Month: Here's Why

Inovio Pharma (INO) rises 19% this month after the FDA issues positive feedback on data from a phase I/II study on a rare respiratory disease candidate, INO-3107, which can be used to file a BLA.

Yahoo | October 19, 2023

INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) that data from its completed Phase 1/2 trial of INO-3107 for the treatment of RRP could support INOVIO's submission of a BLA for review under the FDA's accelerated approval program. The FDA also advised that the

Yahoo | October 10, 2023

Inovio spinoff Geneos raises another $5M to advance therapeutic cancer vaccines

A Montgomery County biotherapeutics company developing personalized therapeutic cancer vaccines said Thursday it has completed its series A3 financing round with an additional investment of $5 million. Geneos Therapeutics of Plymouth Meeting has now raised a total of $10 million from the round, and more than $36 million since its inception. The new investment adds Shanghai Healthcare Capital, a private equity firm based in China, to the company's investor syndicate.

Yahoo | September 28, 2023

Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million

Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced that it has completed its Series A3 financing round with an additional investment of $5 million, totaling $10 million. This investment adds Shanghai Healthcare Capital (SHC) to Geneos' investor syndicate. Dr. Jing Bao will join as a board observer, bringing extensive expertise in the pharmaceutical industry and with global clinical trials.

Yahoo | September 27, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!